WOODBRIDGE, ON, Sept. 3, 2014 /PRNewswire/ – Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), (“Pivotal” or the “Company”), a specialty pharmaceutical company with a
focus on Omega-3 therapies for cardiovascular disease (“CVD”) and
overall health, announced today that the cardio-protective effects of
Pivotal’s unique Omega-3 formulation commercialized as VASCAZEN® was presented at the 2014 Annual Scientific Meeting of the European
Society of Cardiology (“ESC”) Congress 2014 in Barcelona, Spain, by
Rasul et al. from the Laboratory of Biophotonics and Pharmacology of
the University of Strasbourg, France.
The presented poster, entitled “Chronic oral intake of the omega 3 optimized formulation EPA:DHA 6:1
protects against angiotensin II-induced hypertension and endothelial
dysfunction in rats,” indicated that chronic intake of VASCAZEN®‘s EPA:DHA 6:1 prevented the development of hypertension and endothelial
dysfunction in a rodent model. The vasoprotective and antihypertensive
effects of VASCAZEN® is mediated by an improvement of both the nitric oxide (NO) and the
EDH-mediated relaxations as well as a reduction of
endothelium-dependent contractile response.
“These findings show that formulation, purity and dose plays a
significant role in biological activity,” said Dr. George Jackowski,
Chief Scientific Officer. “Until now, many Cardiologists believed that
all Omega-3’s had similar vasodilatory effects, regardless of
formulation. We are very pleased to have had this opportunity to
educate the attendees of the ESC Congress about the unique VASCAZEN® EPA:DHA 6:1 formulation and its proven clinical superiority over other
existing commercial products in the marketplace in terms of sustained
coronary vasodilation (i.e. increase of blood flow).”
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF; CSE:PVO), specialty pharmaceutical company with a focus on cardiovascular
disease and overall health. Pivotal Therapeutics’ lead product VASCAZEN® is a prescription only medical food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications. OMAZEN® is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in
each capsule for the maintenance of good health. OMAZEN® is a patented product available for sale and distribution in Canada.
VASCAZEN® is currently available in the U.S. as a prescription only medical food
specifically formulated for the dietary management of an Omega-3
deficiency in cardiovascular patients. VASCAZEN® is a 90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign patents.
VASCAZEN® has been clinically shown to correct an Omega-3 deficiency within eight
weeks of treatment with positive concomitant effects on the lipid
profiles, mainly a 48% reduction of triglycerides and an increase of
HDL without negative impact on the LDL-C lipid profile. VASCAZEN®‘s results were achieved with a dose of 3 grams of EPA and DHA per day
of a prescription grade, high purity, uniquely formulated Omega-3.
The information contained in this document is as of September 3, 2014.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal’s actual results
to differ materially from those projected in such forward-looking
statements. These statements can be identified by the use of words such
as “will”, “anticipate”, “estimate”, “expect”, “project”, “forecast”,
“intend”, “plan”, “believe”, “project”, “potential”, and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause actual
results to differ materially from those in forward looking statements
include the following: Pivotal’s inability to obtain additional
financing on acceptable terms; growth in costs and expenses; inability
to compete with others who provide comparable products; risk that the
Company’s products will not gain widespread market acceptance; risks
relating to the Company’s ability to maintain its CSE listing.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. The Company undertakes no obligation
to publicly update or revise any forward-looking statements contained
in this document as a result of new information or future events or
developments. The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.